报价延迟最少15分钟:2025/07/21 16:19 EDT
盘后时段
|
||||
|
0.614 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.614
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.51/-2.76
|
|
企业价值
19.15M
|
| 资产负债 |
|
每股账面净值
0.68
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
0.00
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 16:19 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous systemdiseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications. |
